Compounded vs Branded GLP-1: Why Not Take the Cheaper One?

You have seen GLP-1 plans advertised at $99 a month, and you may know someone who orders a compounded vial and is happy with it. You are not going to do that. You want a branded pen with a name you recognize, a clinician who has read your bloodwork, and the numbers in front of you. A fair question still comes back to you, from your own spreadsheet or from whoever sees the card statement: why not compounded, if it is cheaper?

This piece answers that question on the merits of compounded vs branded GLP-1. It uses dated prices and the FDA's public record, and it says plainly what GoodLife Health charges, what the membership does and does not include, and who should choose something else. We have a stake in the answer, because our clinicians prescribe branded medication only, so weigh what follows with that in mind.

The cheaper option is real, and the question is fair

Start with what is true. Compounded GLP-1 has been the cheapest way into these medicines, and the low end of the market is the $99-a-month compounded app. Branded medication costs more. Through NovoCare, Novo Nordisk's own pharmacy program, Wegovy pens were listed in September 2026 at $199 a month for the first two fills, an introductory offer for new patients through December 2026, and $349 a month after that, according to NovoCare's Wegovy page. Through LillyDirect, Zepbound vials were $299 to $449 a month depending on dose, according to Lilly's Zepbound savings page. Add a membership to either and the gap with a $99 plan is plain to see. Nobody should pretend otherwise.

You are used to paying for quality, and you are also used to being sold a label. You pay more for the better accountant or the better flight, and you can usually say what the extra money buys. With a GLP-1 that is harder, because the active ingredient carries the same name on the pen and on the vial, and the people around you who chose the cheaper route mostly seem fine. Many of them are fine. For roughly three years, millions of people used compounded copies legally, and they did nothing wrong.

So the instinct that keeps you away from a vial deserves a reason behind it, partly so you can stand by the decision and partly so you can explain it to someone else. There is a reason, and it rests on three facts: what happened to compounding in 2025, who answers for what ends up in your body, and what a low price tells you about the business behind it.

There is also your own time to consider. A plan that is cheap per month but sends you to one place for labs, another clinician for your blood pressure or thyroid, and an app for the medicine asks you to be the coordinator. Three providers who never see each other's results leave you carrying the file between them, and coordinating your own care is the job you were trying to hand to someone qualified.

What actually separates a compounded vial from a branded pen

The legal basis for mass compounding ended in 2025

When a medicine is on the FDA's drug shortage list, federal law lets pharmacies make copies of it to fill the gap. Semaglutide and tirzepatide went on that list in 2022 because the manufacturers could not make enough, and a large compounded market grew up around them. Then supply caught up. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved on February 21, 2025. The last enforcement grace period for tirzepatide compounding ended on March 19, 2025. For semaglutide, the grace period ended on April 22, 2025 for state-licensed (503A) pharmacies and on May 22, 2025 for outsourcing facilities (503B). In 2026 the FDA proposed permanently excluding both medicines from the list that outsourcing facilities may compound in bulk.

The compounding industry's trade group sued to stop the shortage determinations, and federal courts declined to block them. Both manufacturers have also sued companies selling compounded versions. What remains is a narrow exception: a pharmacy may still compound a medicine for one specific patient who has a documented clinical need the branded product cannot meet, such as an allergy to an ingredient. Some companies continue to sell compounded GLP-1 on that basis. Whether a particular company's use of the exception is appropriate is a legal and clinical question we will not try to answer for you. In plain terms, a plan still built on compounded GLP-1 in 2026 rests on an exception rather than a rule, and that is worth knowing before you build a long-term treatment plan around it.

The FDA's position is public. Compounded drugs are not reviewed by the agency for safety or effectiveness, and the FDA has published its concerns about unapproved GLP-1 drugs used for weight loss, including reports of dosing errors and of compounded versions made with added ingredients. Those are facts about oversight and reported problems. We do not claim that every compounded vial is unsafe, and this piece does not ask you to believe that.

The evidence describes the branded products

The results people quote for these drugs come from large published trials of the branded products. In the STEP 1 trial, 1,961 adults on semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks. In SURMOUNT-1, 2,539 adults on tirzepatide 15 mg lost an average of 20.9% over 72 weeks. Those are averages, from trials that excluded many common conditions; some people lose more, some lose less, and no one can promise you either figure. What the trials do tell you is which product the evidence describes. A branded pen is the product that was tested and approved. A compounded vial is a pharmacy's preparation of the same active ingredient that has not been through that review.

For a reader who wants the data, that distinction is the point. When you and your clinician look at your own numbers three months in, you want to compare them against evidence gathered on the thing you are taking.

Someone answers for every prescription

Every prescription has a name on it. The clinician who writes it answers for that decision under their license, and the pharmacy answers for what it dispenses. When the choice is between an FDA-approved product with published trials behind it and a copy whose oversight the FDA has publicly questioned, a careful clinician is deciding what they are willing to put their license behind. Our clinicians prescribe branded, FDA-approved medication only. That choice has a cost to our members, which is the branded price, and we would rather tell you so than hide it.

A low price also tells you how a company is paid

A monthly price tells you how a company earns its money, and how a company earns its money is the pressure its clinicians work under. Many low-fee telehealth plans earn their real margin on the medication: the membership looks small and the profit sits in what you pay for the drug. That happens with branded medicine too. The comparison chart in our plain-language white paper on how GLP-1 telehealth companies make money, compiled from public pricing pages in May 2026, found branded Zepbound or Mounjaro offered at up to $1,899 a month through legacy telehealth memberships. Lilly's own self-pay price for Zepbound vials was $299 to $449 a month depending on dose in September 2026. So when you hear that branded costs far more, ask whose price you are hearing: the manufacturer's, or that of a company in the middle that adds its own.

This matters if you want a clinician on your side. When a company's revenue rises with the medication, it is rewarded, quietly, for more prescribing and faster dose increases. Nobody has to be dishonest for that pressure to exist, and you are entitled to know which way it points before you choose.

What GoodLife Health does instead, and what it costs

GoodLife Health is clinician-led precision direct primary care for Cardiometabolic Optimization. It is labs-first: diagnosis first, then treatment, then the long haul. The membership is $299 a month, month to month. At sign-up, $598 is charged and covers the first two months. If the clinician cannot accept you into care, the $598 is refunded in full; once you are accepted, the first two months are non-refundable. Medication billed by a pharmacy follows that pharmacy's own return and refund policy. Over a full year, the membership is $3,588.

The fee covers clinicians licensed in all fifty states, four cardiometabolic lab panels a year, every result in your hands, asynchronous messaging with the care team, and video visits. The fee is the same whatever medication is indicated and whatever the dose, so there is no upcharge for moving from one molecule to another and none for a higher dose. The membership fee is generally eligible for HSA or FSA pre-tax dollars.

The labs are the center of the model. The panels come quarterly, every result is put in your hands, and a clinician reads them before deciding anything: whether a GLP-1 is indicated at all, which one, and at what dose. If your numbers improve, the protocol follows them, and nothing in the way we are paid resists a lower dose or a taper. That is what zero-markup Aligned Medicine means in practice: the membership is our only revenue from your care, so the business has no reason to prefer a stronger prescription.

Medication is unbundled. When it is clinically indicated, it is prescribed to the pharmacy you choose, at that pharmacy's own price. GoodLife Health sets nothing, sees nothing and takes nothing on medication. For GLP-1 therapy that means Wegovy, Zepbound, Mounjaro or Ozempic, and never a compounded copy. If you pay cash, the manufacturers' published self-pay programs are one route: the September 2026 NovoCare and LillyDirect prices above, and the Wegovy pill from $149 a month at lower doses. Your total is the membership plus whatever your pharmacy charges. We do not set that second number, so we cannot quote it as ours.

The care is built for a full calendar. Asynchronous messaging means you write to the care team when you have a minute, rather than when an office is open, and video visits are there when a conversation is the better tool. The labs, the messages and the prescribing decisions sit with one care team, so you are no longer the person carrying results from one provider to the next.

The membership pairs with insurance for catastrophic coverage; it does not replace insurance. It replaces the primary-care relationship. If you would like your plan to pay for a branded GLP-1, that is between you, your plan and your pharmacy. Prior authorization is the pharmacy's process. We do not run it, speed it or promise its outcome, and we never promise that a medication will be covered.

As for where this sits, GoodLife Health is between the $20,000-a-year concierge practice and the $99-a-month compounded app. You get a clinician who reads every panel and a fee that does not move with your prescription, without a concierge retainer, and you pay the branded price for medication rather than the compounded one.

What the membership does not do matters as much. It does not guarantee weight loss or any other result. It does not prescribe compounded GLP-1 under any circumstances, so if the compounded price is the deciding factor, we cannot meet it. And it is not open to everyone: the path is the eligibility check, the intake, the checkout, then a clinician's review, and some people are not accepted.

Is the branded price worth it for you?

If you have read this far, you probably did not need persuading away from a vial. What you needed was a way to say why, in a sentence you could repeat to someone who sees only the price. The compounded price buys a pharmacy's copy whose large-scale legal basis ended in 2025; the branded price buys the product that was tested, approved and priced in public by its maker.

The second question is the one people skip: what you are paying the company in the middle for. A membership that costs more per month but takes nothing on the medicine, puts four lab panels a year in your hands and keeps the same fee whatever you are prescribed is a different purchase from a cheap plan whose margin sits in the drug. Price any options honestly, with each side's full year and the dates of the prices you used, and decide on the whole picture rather than the monthly headline.

Whatever you choose, three questions will tell you most of what you need to know about any plan, ours included. Where does its money come from: the membership, the medication, or your insurance? Will the fee change if your medication or dose changes? Will you see your own lab results on a schedule, read by a clinician who sets the protocol from them? A plan that answers all three clearly is giving you what you need to judge it.

If the numbers still do not work for you this year, that is a legitimate answer. It is better to choose care you can sustain than to start a plan you will leave in three months.

Who this is not for

If the lowest possible monthly price is your main test, GoodLife Health is not for you, and we would rather say so now than after a checkout. We do not compete with the $99-a-month compounded app, and we will not prescribe compounded GLP-1 to match it. The membership is also wrong for someone who wants a medication sent without labs and a clinician's review, someone looking for a guaranteed result, or someone hoping a membership will stand in for health insurance. And if you already have a primary-care clinician you trust, labs you see regularly, and a plan that covers your medication, you may not need us at all.

Related Reading

• How GLP-1 Telehealth Companies Make Money: A Plain-Language Whitepaper
• Aligned Medicine: How Zero-Markup Healthcare Actually Works

References

1. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
2. NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
3. Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
4. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/
5. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/